MRANK-106 / MindRank AI - LARVOL DELTA

Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline (GlobeNewswire) - "MindRank...announces today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MRANK-106, a first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the treatment of pancreatic cancer, small cell lung cancer, ovarian cancer, breast cancer, and colorectal cancer....The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of MRANK-106 in patients with advanced or metastatic solid tumors."

IND • New P1 trial • Breast Cancer • Colorectal Cancer • Ovarian Cancer • Pancreatic Cancer • Small Cell Lung Cancer